Literature DB >> 30531394

Rupture of the Patellar Tendon After Platelet-Rich Plasma Treatment: A Case Report.

Andrea Redler1, Lorenzo Proietti, Daniele Mazza, Guido Koverech, Antonio Vadala, Angelo De Carli, Andrea Ferretti.   

Abstract

INTRODUCTION: Rupture of the patellar tendon is becoming more and more frequent, even in sports activities overloading the extensor mechanism of the knee. Platelet-rich plasma (PRP) treatment has been recently introduced in treatment for several knee- and sport-related injuries including muscle strain cartilage defect and tendinopathies. The aim of this case report is to present a case of rupture of the patellar tendon occurred after injections of PRP. CASE REPORT: A case of a 40-year-old male soccer player sustaining a patellar tendon rupture after a series of 4 PRP injections. At surgery, a complete rupture in the middle of the patellar tendon was found, with severe degenerative changes of the tendon tissue. This case questions the actual efficacy and safety of PRP in severe degenerative tendinopathies.

Entities:  

Mesh:

Year:  2020        PMID: 30531394     DOI: 10.1097/JSM.0000000000000703

Source DB:  PubMed          Journal:  Clin J Sport Med        ISSN: 1050-642X            Impact factor:   3.638


  3 in total

1.  Poorer functional Outcomes in Patients with Multi-Ligamentous Knee Injury with Concomitant Patellar Tendon Ruptures at 5 years Follow-Up.

Authors:  Edward S Mojica; Andrew S Bi; Kinjal Vasavada; Jay Moran; Scott Buzin; Joseph Kahan; Erin F Alaia; Laith M Jazrawi; Michael J Medvecky; Michael J Alaia
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2022-09-01       Impact factor: 4.114

2.  Allergic reaction to platelet-rich plasma (PRP): Case report.

Authors:  Michal Latalski; Alicja Walczyk; Marek Fatyga; Erich Rutz; Tomasz Szponder; Tomasz Bielecki; Anna Danielewicz
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.817

3.  Platelet-rich plasma versus corticosteroid injection for treatment of trigger finger: study protocol for a prospective randomized triple-blind placebo-controlled trial.

Authors:  Samuli Aspinen; Panu H Nordback; Turkka Anttila; Susanna Stjernberg-Salmela; Jorma Ryhänen; Jussi Kosola
Journal:  Trials       Date:  2020-11-27       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.